A multicenter, randomized, participant- and investigator -blinded, placebo-controlled, phase 2a study to assess the efficacy, safety and tolerability of GIA632 in adult participants with moderate to severe atopic dermatitis

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521503-43-00

Acronym

CGIA632A12201

Enrollment

Registered

2026-01-14

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Brief summary

IGA response at week 16 defined as clear (0) or almost clear (1) score with at least a 2 point-reduction from baseline

Detailed description

Treatment-emergent adverse events (TEAEs) until End of Study (EoS)

Interventions

DRUGPlacebo to GIA632 150 mg/mL solution for injection

DRUGGIA632

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
IGA response at week 16 defined as clear (0) or almost clear (1) score with at least a 2 point-reduction from baseline	—

Secondary

Measure	Time frame
Treatment-emergent adverse events (TEAEs) until End of Study (EoS)	—

Countries

Bulgaria, Czechia, France, Germany, Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026